Evaluation of cumulative lead dose and longitudinal changes in structural magnetic resonance imaging in former organolead workers

Journal of Occupational and Environmental Medicine

Volumn 52, Issue 4, 2010, Pages 407-414

  Schwartz, Brian S ^a   Caffo, Brian ^b   Stewart, Walter F ^a,c   Hedlin, Haley ^b   James, Bryan D ^f   Yousem, David ^d   Davatzikos, Christos ^e  

^a Department of Environmental Health Sciences ^*  (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c GEISINGER MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORGANOLEAD COMPOUND;

ADULT; ARTICLE; BONE LEVEL; BRAIN DAMAGE; BRAIN SIZE; COGNITIVE DEFECT; DISEASE EXACERBATION; GRAY MATTER; HUMAN; INDUSTRIAL WORKER; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL EXPOSURE; TIBIA; WHITE MATTER;

EID: 77951151810     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/JOM.0b013e3181d5e386     Document Type: Article

References (38)

1. Stewart WF, Schwartz BS. Effects of lead on the adult brain: a 15-year exploration. Am J Ind Med. 2007;50:729-739.
2. Theppeang K, Glass TA, Bandeen-Roche K, Todd AC, Rohde CA, Schwartz BS. Gender and race/ethnicity differences in lead dose biomarkers. Am J Public Health. 2008;98:1248-1255.
3. Shih RA, Glass TA, Bandeen-Roche K, et al. Environmental lead exposure and cognitive function in community-dwelling older adults. Neurology. 2006;67:1556-1562.
4. Shih RA, Hu H, Weisskopf MG, Schwartz BS. Cumulative lead dose and cognitive function in adults: a review of studies that measured both blood lead and bone lead. Environ Health Perspect. 2007;115:483-492.
5. Stewart WF, Schwartz BS, Simon D, Bolla KI, Todd AC, Links J. Neurobehavioral function and tibial and chelatable lead levels in 543 former organolead workers. Neurology. 1999;52:1610-1617. (Pubitemid 29220635)
6. Schwartz BS, Stewart WF, Bolla KI, et al. Past adult lead exposure is associated with longitudinal decline in cognitive function. Neurology. 2000; 55:1144-1150.
7. Links JM, Schwartz BS, Simon D, Bandeen-Roche K, Stewart WF. Characterization of toxicokinetics and toxicodynamics with linear systems theory: application to lead-associated cognitive decline. Environ Health Perspect. 2001;109:361-368.
8. Stewart WF, Schwartz BS, Davatzikos C, et al. Past adult lead exposure is linked to neurodegeneration measured by brain MRI. Neurology. 2006;66: 1476-1484.
9. Stewart WF, Schwartz BS, Simon D, Kelsey K, Todd AC. ApoE genotype, past adult lead exposure, and neurobehavioral function. Environ Health Perspect. 2002;110:501-505.
10. Schwartz BS, Chen S, Caffo B, et al. Relations of brain volumes with cognitive function in males 45 years and older with past lead exposure. Neuroimage. 2007;37:633-641.
11. Caffo B, Chen S, Stewart W, et al. Are brain volumes based on magnetic resonance imaging mediators of the associations of cumulative lead dose with cognitive function? Am J Epidemiol. 2008;167:429-437.
12. Schwartz BS, Bolla KI, Stewart W, Ford DP, Agnew J, Frumkin H. Decrements in neurobehavioral performance associated with mixed exposure to organic and inorganic lead. Am J Epidemiol. 1993;137:1006-1021.
13. Glass TA, Rasmussen MD, Schwartz BS. Neighborhoods and obesity in older adults: the Baltimore Memory Study. Am J Prev Med. 2006;31:455-463.
14. Schwartz BS, Glass TA, Bolla KI, et al. Disparities in cognitive functioning by race/ethnicity in the Baltimore Memory Study. Environ Health Perspect. 2004;112:314-320.
15. Alphs HH, Schwartz BS, Stewart WF, Yousem DM. Findings on brain MRI from research studies of occupational exposure to known neurotoxicants. AJR Am J Roentgenol. 2006;187:1043-1047.
16. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263-276.
17. Longstreth WT Jr, Bernick C, Manolio TA, Bryan N, Jungreis CA, Price TR. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol. 1998;55:1217-1225.
18. Goldszal AF, Davatzikos C, Pham DL, Yan MX, Bryan RN, Resnick SM. An image-processing system for qualitative and quantitative volumetric analysis of brain images. J Comput Assist Tomogr. 1998;22:827-837.
19. Kabani N, MacDonald D, Holmes CJ, Evans A. A 3D atlas of the human brain. Neuroimage. 1998;7:S717.
20. Shen D. 4D Image warping for measurement of longitudinal brain changes. In: Proceedings of the IEEE International Symposium on Biomedical Imaging. Vol.1. Arlington, Va: IEEE; 2004 904-907.
21. Andreasen NC, Rajarethinam R, Cizadlo T, et al. Automatic atlas-based volume estimation of human brain regions from MR images. J Comput Assist Tomogr. 1996;20:98-106.
22. Resnick SM, Goldszal AF, Davatzikos C, et al. One-year age changes in MRI brain volumes in older adults. Cereb Cortex. 2000;10:464-472.
23. Xue Z, Shen D, Davatzikos C. CLASSIC: consistent longitudinal alignment and segmentation for serial image computing. Neuroimage. 2006;30:388-399.
24. Rorden C, Brett M. Stereotaxic display of brain lesions. Behav Neurol. 2000;12:191-200.
25. Schwartz BS, Stewart WF. Lead and cognitive function in adults: a questions and answers approach to a review of the evidence for cause, treatment, and prevention. Int Rev Psychiatry. 2007;19:671-692.
26. Rowland AS, McKinstry RC. Lead toxicity, white matter lesions, and aging. Neurology. 2006;66:1464-1465.
27. Resnick SM, Pham DL, Kraut MA, Zonderman AB, Davatzikos C. Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci. 2003;23:3295-3301.
28. Fotenos AF, Mintun MA, Snyder AZ, Morris JC, Buckner RL. Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol. 2008;65:113-120.
29. Chen K, Reiman EM, Alexander GE, et al. Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. Am J Psychiatry. 2007;164:916-921.
30. Enzinger C, Fazekas F, Matthews PM, et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology. 2005;64:1704-1711.
31. Schmidt R, Ropele S, Enzinger C, et al. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian stroke prevention study. Ann Neurol. 2005;58:610-616.
32. Liu RS, Lemieux L, Bell GS, et al. A longitudinal study of brain morphometrics using quantitative magnetic resonance imaging and difference image analysis. Neuroimage. 2003;20:22-33.
33. Bernick C, Katz R, Smith NL et al; Cardiovascular Health Study Collaborative Research Group. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology. 2005;65:1388-1394.
34. Mueller EA, Moore MM, Kerr DC, et al. Brain volume preserved in healthy elderly through the eleventh decade. Neurology. 1998;51:1555-1562.
35. Tang Y, Whitman GT, Lopez I, Baloh RW. Brain volume changes on longitudinal magnetic resonance imaging in normal older people. J Neuroimaging. 2001;11:393-400.
36. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351-357.
37. Fotenos AF, Snyder AZ, Girton LE, Morris JC, Buckner RL. Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology. 2005;64:1032-1039.
38. Xue Z, Shen D, Davatzikos C. CLASSIC: consistent longitudinal alignment and segmentation for serial image computing. Inf Process Med Imaging. 2005;19:101-113.